Eupalitin

Eupalitin is a naturally occurring O-methylated flavone found in plants such as Eupatorium and Artemisia species, belonging to the broader flavonoid class of polyphenolic compounds. Its primary investigated mechanism involves inhibition of angiotensin-converting enzyme (ACE), suggesting potential antihypertensive activity based on molecular docking data.

Origin & History

Eupalitin is a flavone compound (3,5,4'-trihydroxy-6,7-dimethoxyflavone) naturally occurring in plants including Artemisia annua, Aeonium glutinosum, Arnica montana, and Boerhavia diffusa. It is extracted using methanol extraction followed by ethyl acetate partitioning and crystallization methods.

Historical & Cultural Context

No specific traditional medicinal uses for eupalitin itself are documented. While found in plants like Boerhavia diffusa that have traditional applications, eupalitin as an isolated compound lacks documented historical use.

Health Benefits

• Potential antihypertensive effects through ACE inhibition (preliminary evidence from molecular docking studies showing -7.89 kcal/mol binding score)
• Possible cardiovascular protective properties (theoretical based on flavone class characteristics, no direct clinical evidence)
• Potential hepatoprotective activity (preliminary evidence from rat studies only)
• Theoretical antioxidant properties (based on flavone structure, no specific eupalitin studies)
• Possible anti-inflammatory effects (theoretical based on flavone class, no direct eupalitin evidence)

How It Works

Eupalitin has demonstrated binding affinity to angiotensin-converting enzyme (ACE) at a docking score of -7.89 kcal/mol in computational studies, suggesting it may competitively inhibit ACE-mediated conversion of angiotensin I to the vasoconstrictive peptide angiotensin II, thereby potentially reducing peripheral vascular resistance. As an O-methylated flavone, eupalitin may also modulate oxidative stress pathways by scavenging reactive oxygen species (ROS) and interacting with Nrf2-mediated antioxidant response elements, consistent with mechanisms observed across the flavone subclass. Hepatoprotective activity, where preliminary data exists, is theorized to involve attenuation of NF-κB inflammatory signaling and reduction of lipid peroxidation in hepatocyte models.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on eupalitin. Current research is limited to preclinical studies including in silico molecular docking and rat models testing its glycoside form (eupalitin 3-O-β-D-galactopyranoside) for antihypertensive effects.

Clinical Summary

To date, no published human clinical trials have evaluated eupalitin as an isolated compound, meaning all efficacy data originates from in silico (molecular docking), in vitro (cell culture), or limited in vivo (animal) studies. The strongest available evidence is a computational binding study reporting a -7.89 kcal/mol ACE inhibition score, which is hypothesis-generating but does not confirm pharmacological activity in living systems. Cardiovascular and hepatoprotective claims are largely extrapolated from the broader flavone and flavonoid literature, where compounds with similar methylation patterns have shown measurable effects in rodent models. The overall evidence base for eupalitin-specific health benefits must be characterized as preliminary and insufficient to support therapeutic recommendations without rigorous controlled trials.

Nutritional Profile

Eupalitin (3',4',5,7-tetrahydroxy-6-methoxyflavone) is a pure isolated flavone compound, not a whole food ingredient, and therefore lacks conventional macronutrient or micronutrient content. As a bioactive compound, its relevant profile is defined by its molecular and phytochemical characteristics: Molecular formula C16H12O7, molecular weight approximately 320.26 g/mol. It belongs to the flavone subclass of flavonoids, structurally characterized by a 6-methoxy substitution on the A-ring alongside hydroxyl groups at positions 3', 4', 5, and 7. Bioactive compound concentration when isolated is nominally 100% pure compound; in natural plant sources such as Eupatorium species and some Asteraceae family plants, it occurs in trace quantities typically in the range of 0.01–0.5% dry weight depending on plant part and extraction method. No vitamins, dietary minerals, dietary fiber, or protein content are applicable to this isolated compound. Bioavailability data in humans is absent; preliminary pharmacokinetic inference from structurally analogous flavones (e.g., luteolin, apigenin) suggests potential oral bioavailability of 5–20%, likely subject to extensive phase II metabolism (glucuronidation and sulfation) and gut microbiome biotransformation. The methoxy group at C-6 may modestly enhance lipophilicity compared to non-methoxylated analogs, potentially improving membrane permeability (estimated logP approximately 1.8–2.3). No established dietary reference values or tolerable upper intake levels exist for eupalitin specifically.

Preparation & Dosage

No clinically studied dosage ranges are available for eupalitin due to absence of human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other flavonoids, ACE inhibitors, cardiovascular support compounds, antioxidants, hepatoprotective herbs

Safety & Interactions

No dedicated human safety or toxicology trials have been conducted specifically for isolated eupalitin, making it impossible to establish a confirmed adverse effect profile or maximum tolerable dose at this time. Because eupalitin may inhibit ACE activity based on computational evidence, concurrent use with prescription ACE inhibitors (e.g., lisinopril, enalapril) or angiotensin receptor blockers (ARBs) represents a theoretical additive hypotensive interaction risk that warrants caution. As a flavonoid, eupalitin could theoretically influence cytochrome P450 enzyme activity (particularly CYP3A4 and CYP1A2), potentially altering metabolism of co-administered drugs, though this has not been directly studied for eupalitin. Pregnant and breastfeeding individuals should avoid supplementation given the complete absence of reproductive safety data.